Optimal timing of a γH2AX analysis to predict cellular lethal damage in cultured tumor cell lines after exposure to diagnostic and therapeutic radiation doses.
DNA repair
clonogenic cell survival
double-strand break (DSB)
gammaH2AX (γH2AX)
low-dose radiation
Journal
Journal of radiation research
ISSN: 1349-9157
Titre abrégé: J Radiat Res
Pays: England
ID NLM: 0376611
Informations de publication
Date de publication:
23 Mar 2023
23 Mar 2023
Historique:
received:
14
10
2022
revised:
24
11
2022
pubmed:
13
1
2023
medline:
28
3
2023
entrez:
12
1
2023
Statut:
ppublish
Résumé
Phosphorylated H2AX (γH2AX) is a sensitive biomarker of DNA double-strand breaks (DSBs). To assess the adverse effects of low-dose radiation (<50 mGy), γH2AX levels have typically been measured in human lymphocytes within 30 min of computed tomography (CT) examinations. However, in the presence of DSB repair, it remains unclear whether γH2AX levels within 30 min of irradiation completely reflect biological effects. Therefore, we investigated the optimal timing of a γH2AX analysis to predict the cell-surviving fraction (SF). Three tumor cell lines were irradiated at different X-ray doses (10-4000 mGy), and the relationships between SF and relative γH2AX levels were investigated 15 min and 2, 6, 12 and 24 h after irradiation. Data were analyzed for high-dose (0-4000 mGy) and low-dose (0-500 mGy) ranges. Correlations were observed between SF and the relative number of γH2AX foci/nucleus at 12 h only (R2 = 0.68, P = 0.001 after high doses; R2 = 0.37, P = 0.016 after low doses). The relative intensity of γH2AX correlated with SF 15 min to 12 h after high doses and 2 to 12 h after low doses, with the maximum R2 values being observed 2 h after high doses (R2 = 0.89, P < 0.001) and 12 h after low doses (R2 = 0.65, P < 0.001). Collectively, cellular lethal damage in tumor cells was more accurately estimated with residual DSBs 12 h after low-dose (10-500 mGy) irradiation. These results may contribute to determination of the optimal timing of biodosimetric analyses using γH2AX in future studies.
Identifiants
pubmed: 36634337
pii: 6984806
doi: 10.1093/jrr/rrac096
pmc: PMC10036098
doi:
Substances chimiques
Histones
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
317-327Subventions
Organisme : JSPS
ID : 18K07725
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of The Japanese Radiation Research Society and Japanese Society for Radiation Oncology.
Références
Br J Cancer. 2003 Aug 4;89(3):593-601
pubmed: 12888835
Nature. 2006 Jan 26;439(7075):497-501
pubmed: 16299494
Dose Response. 2020 Feb 17;18(1):1559325820907011
pubmed: 32110172
Biochem Biophys Res Commun. 2005 Oct 28;336(3):807-12
pubmed: 16153602
Cytometry A. 2015 Dec;87(12):1138-46
pubmed: 26305808
Cancer Res. 2004 Oct 1;64(19):7144-9
pubmed: 15466212
Int J Radiat Biol. 2009 Nov;85(11):1032-41
pubmed: 19895280
Int J Radiat Biol. 2003 May;79(5):351-8
pubmed: 12943243
Dose Response. 2020 May 05;18(2):1559325820923828
pubmed: 32425727
Crit Rev Biochem Mol Biol. 2011 Aug;46(4):271-83
pubmed: 21524151
Lancet. 2012 Aug 4;380(9840):499-505
pubmed: 22681860
Dose Response. 2019 Apr 22;17(2):1559325819842733
pubmed: 31040760
BMJ. 2013 May 21;346:f2360
pubmed: 23694687
Cell Cycle. 2010 Feb 15;9(4):662-9
pubmed: 20139725
Biol Reprod. 2004 Aug;71(2):643-9
pubmed: 15115728
Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1498-505
pubmed: 17126209
Radiat Res. 2017 Oct;188(4.2):505-511
pubmed: 28742468
Br J Cancer. 1994 Mar;69(3):457-62
pubmed: 8123473
J Biomed Phys Eng. 2018 Dec 01;8(4):393-402
pubmed: 30568929
Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):481-90
pubmed: 10661357
Int J Radiat Oncol Biol Phys. 2004 Aug 1;59(5):1484-90
pubmed: 15275736
Radiat Res. 2017 Oct;188(4.2):495-504
pubmed: 28741984
J Urol. 2014 Mar;191(3):842-9
pubmed: 24035881
J Radiat Res. 2009 Mar;50(2):151-60
pubmed: 19202324
Mol Cell. 2005 Dec 9;20(5):801-9
pubmed: 16310392
Br J Cancer. 2004 Apr 5;90(7):1297-301
pubmed: 15054444
Dose Response. 2017 Oct 12;15(4):1559325817735252
pubmed: 29051717
Dose Response. 2020 Apr 29;18(2):1559325820921641
pubmed: 32425724
Genes (Basel). 2020 Jan 04;11(1):
pubmed: 31947954
EMBO J. 2009 Nov 4;28(21):3413-27
pubmed: 19779458
Radiology. 2004 May;231(2):440-5
pubmed: 15128988
Transl Cancer Res. 2021 Jun;10(6):2767-2776
pubmed: 35116587
BMC Cancer. 2010 Jan 05;10:4
pubmed: 20051134
Radiology. 2007 Jan;242(1):244-51
pubmed: 17185671
Cancer Res. 2001 May 15;61(10):3886-93
pubmed: 11358801
Int J Radiat Biol. 2007 May;83(5):319-29
pubmed: 17457757
Radiology. 2020 May;295(2):439-445
pubmed: 32154776
Dose Response. 2018 Nov 19;16(4):1559325818811753
pubmed: 30479589
Mol Cell. 2004 Dec 3;16(5):715-24
pubmed: 15574327
Radiat Res. 2010 Aug;174(2):185-94
pubmed: 20681785
J Cell Biol. 1999 Sep 6;146(5):905-16
pubmed: 10477747
Int J Mol Sci. 2018 Aug 13;19(8):
pubmed: 30104556
J Biol Chem. 1998 Mar 6;273(10):5858-68
pubmed: 9488723
Proc Natl Acad Sci U S A. 2005 Jun 21;102(25):8984-9
pubmed: 15956203
Eur Radiol. 2015 Mar;25(3):800-11
pubmed: 25354556
Int J Radiat Biol. 1995 Jan;67(1):7-18
pubmed: 7852819